Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial – AstraZeneca

by

  1. Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial AstraZeneca
  2. AstraZeneca, Daiichi hit first goal in breast cancer ADC trial FierceBiotech
  3. AstraZeneca, Daiichi breast cancer treatment succeeds in trial STAT
  4. Dr Liu on the 5-Year OS Data With Atezolizumab and Chemotherapy in ES-SCLC OncLive
  5. AstraZeneca and Daiichi’s breast cancer drug meets goal in study Reuters
  6. View Full Coverage on Google News

Read original article here

Leave a Comment